Evidence map›Paper›PMID 38595332›Full record

ArticleAsian journal of pharmaceutical sciences2024

Acidic/hypoxia dual-alleviated nanoregulators for enhanced treatment of tumor chemo-immunotherapy.

Xiaoju Guo, Xiaoxiao Chen, Jiayi Ding, Feng Zhang, Shunyang Chen, Xin Hu, Shiji Fang, Lin Shen, Chenying Lu, Zhongwei Zhao and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian journal of pharmaceutical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Xiaoju GuoLishui Central Hospital, Shaoxing University, Shaoxing 312000, China.
Xiaoxiao ChenZhejiang Key Laboratory of Imaging and Interventional Medicine, Imaging Diagnosis and Interventional Minimally Invasive Institute, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Jiayi DingZhejiang Key Laboratory of Imaging and Interventional Medicine, Imaging Diagnosis and Interventional Minimally Invasive Institute, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Feng ZhangZhejiang Key Laboratory of Imaging and Interventional Medicine, Imaging Diagnosis and Interventional Minimally Invasive Institute, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Shunyang ChenLishui Central Hospital, Shaoxing University, Shaoxing 312000, China.
Xin HuLishui Central Hospital, Shaoxing University, Shaoxing 312000, China.
Shiji FangZhejiang Key Laboratory of Imaging and Interventional Medicine, Imaging Diagnosis and Interventional Minimally Invasive Institute, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Lin ShenZhejiang Key Laboratory of Imaging and Interventional Medicine, Imaging Diagnosis and Interventional Minimally Invasive Institute, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Chenying LuLishui Central Hospital, Shaoxing University, Shaoxing 312000, China.
Zhongwei ZhaoLishui Central Hospital, Shaoxing University, Shaoxing 312000, China.
Jianfei TuLishui Central Hospital, Shaoxing University, Shaoxing 312000, China.
Gaofeng ShuZhejiang Key Laboratory of Imaging and Interventional Medicine, Imaging Diagnosis and Interventional Minimally Invasive Institute, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Minjiang ChenZhejiang Key Laboratory of Imaging and Interventional Medicine, Imaging Diagnosis and Interventional Minimally Invasive Institute, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Jiansong JiLishui Central Hospital, Shaoxing University, Shaoxing 312000, China.
Shaoxing University · CNWenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy plays a crucial role in triple-negative breast cancer (TNBC) treatment as it not only directly kills cancer cells but also induces immunogenic cell death. However, the chemotherapeutic efficacy was strongly restricted by the acidic and hypoxic tumor environment. Herein, we have successfully formulated PLGA-based nanoparticles concurrently loaded with doxorubicin (DOX), hemoglobin (Hb) and CaCO

Indexed as

Acidity neutralizationCaCO3-based nanoparticlesEnhanced chemo-immunotherapyHypoxia attenuationReversal of chemotherapy resistance

Identifiers

PMID38595332
PMCPMC11002573
OpenAlexW4392883159

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.